TAFI gene polymorphisms in patients with cerebral venous thrombosis

Tokgoz S., Zamani A. G., Durakbasi-Dursun H. G., YILMAZ O., Ilhan N., Demirel S., ...More

ACTA NEUROLOGICA BELGICA, vol.113, no.3, pp.291-297, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 113 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1007/s13760-012-0170-6
  • Journal Name: ACTA NEUROLOGICA BELGICA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.291-297
  • Keywords: TAFI, Cerebral venous thrombosis, 438G > A, 505A > G, 1040C > T, Sinus thrombosis, ACTIVATABLE FIBRINOLYSIS INHIBITOR, ISCHEMIC-STROKE, MYOCARDIAL-INFARCTION, ANTIGEN LEVELS, INCREASED RISK, PLASMA-LEVELS, ASSOCIATION, DISEASE, THROMBOEMBOLISM, IDENTIFICATION
  • Dokuz Eylül University Affiliated: Yes

Abstract

Gene polymorphisms of thrombin activatable fibrinolysis inhibition (TAFI) factor have been investigated in various studies in terms of etiology (recurrence) and treatment (fibrinolytic effect) of thrombus formation. Cerebral venous thrombosis (CVT) is a life-threatening disease observed in young persons. Fifty-nine patients with CVT and 100 healthy control subjects were enrolled in the case/control study. The association between TAFI gene polymorphisms -438G > A, +505A > G and +1040C > T and cerebral venous thrombosis was investigated. It was found that frequencies of polymorphic genotype and allele were not different in patients than in control group and that they were not significant for cerebral venous thrombosis.